#South Korea #Pixelgen Technologies #Proxiome Kit #MDxK #Gwacheon

Expanding Horizons for Life Sciences in South Korea

Pixelgen Technologies, known for its ground-breaking advances in molecular biology, is setting its sights on the Korean market with a new distribution agreement with MDxK (Molecular Diagnostics Korea). This partnership marks a significant milestone for both companies, as it aims to distribute the innovative Pixelgen Proxiome Kit to researchers and laboratories across South Korea.

The Proxiome Kit is a pioneering product designed to analyze the spatial positioning of cell surface protein markers. This innovation is positioned as a transformative tool for researchers in various fields, including immunology, hematology, and cancer research. The kit allows for detailed insights into protein clustering, colocalization, and abundance data, garnering interest as a powerful resource for understanding cellular mechanisms and discovering new biomarkers.

A Thriving Ecosystem for Innovation

As global demand for advanced tools in the life sciences sector grows, South Korea is rapidly emerging as a powerhouse of innovation in drug development and precision medicine. Pixelgen's Chief Marketing Officer, Annika Branting, emphasized the significance of this market, noting, "South Korea is fast emerging as a life sciences hub of innovation, leading advancements in drug development and, more specifically, precision medicine."

Branting expressed enthusiasm for collaborating with MDxK, stating that the partnership aims to deliver cutting-edge technologies that can empower researchers to explore the molecular intricacies of cellular behaviors. This agreement follows previous distribution efforts by Pixelgen in Japan and Australia, showcasing their commitment to expanding their footprint in the Asia-Pacific region.

The Cutting-Edge Pixelgen Proxiome Kit

The Pixelgen Proxiome Kit utilizes a novel Proximity Network Assay, which employs DNA-based chemistry to assign unique spatial positions to protein targets and their neighbors within single cells. This method achieves an impressive average resolution of 50 nanometers, enabling scientists to produce detailed maps that can encompass up to 50,000 proteins per cell. Such granular detail is not only unprecedented but vital for bioinformatic analyses intended to elucidate complex cell interactions and therapeutic responses.

Specifically, the kit caters to a validated protein panel comprising 155 immune cell surface protein targets. This level of detail offers important insights necessary for consolidating existing knowledge and pushing the boundaries of what is known in basic science and clinical applications.

Enhanced accessibility of this technology through MDxK’s robust distribution strategy reinforces the need for modern solutions in molecular diagnostics, which have historically struggled to keep pace with evolved research methodologies. MDxK CEO, Sungbo Shim, highlighted the unique value of Pixelgen’s offerings, emphasizing that existing tools have fallen short in supporting contemporary omics-scale studies.

Understanding the Strategic Importance of Relationships

MDxK has a long-standing presence in the South Korean life sciences landscape. Established in 2007 and based in Gwacheon, Gyeonggi-do, MDxK caters to various sectors, including hospitals, research laboratories, and pharmaceutical companies, bolstering a comprehensive connection to the life science community. In 2025, the company became a subsidiary of DKSH, a global leader in market expansion services, further reinforcing MDxK's capabilities in delivering cutting-edge technologies to researchers across South Korea.

In conclusion, this strategic agreement not only enhances Pixelgen's platform in the Asia-Pacific market but also addresses an increasing demand for advanced tools in research and clinical diagnostics. By empowering scientists with the technology needed to explore emergent domains in medical research, Pixelgen and MDxK are set to make substantial contributions to the evolution of precision medicine in South Korea and beyond.

With the combined expertise of Pixelgen’s state-of-the-art technologies and MDxK’s established network, the future looks promising for both companies as they work together to enhance research capabilities in South Korea.

About Pixelgen Technologies
Founded in 2020, Pixelgen Technologies AB aims to optimize biological research using innovative tools for deciphering the protein interactomics of single cells. Its patented Proximity Network Assay underpins the Pixelgen Proxiome Kit and is poised to revolutionize the life sciences landscape.

About MDxK
MDxK, part of DKSH, has years of experience delivering reliable solutions across the South Korean life science sector. The company’s collaboration with global industry leaders emphasizes its commitment to advancing molecular diagnostics and life sciences.